Sensitizing Cancer Cells: Is It Really All about U?
Menée in vitro et in vivo, cette étude met en évidence la capacité d'un inhibiteur de TMPK (thymidylate kinase) à rendre les cellules tumorales sensibles à l'action de la doxorubicine
In this issue of Cancer Cell, Hu et al. report that TMPK and RNR, two key enzymes in deoxyribonucleotide biosynthesis, co-localize to damaged DNA and produce nucleotides necessary for DNA repair while suppressing uracil incorporation. TMPK inhibition disrupts this balance and selectively sensitizes cancer cells to low-dose chemotherapy.
Cancer cell , commentaire, 2011